September 15, 2020

Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study indicates PPI use is a negative prognostic marker in advanced urothelial carcinoma treated with ICI therapy, but not chemotherapy. Furthermore, the analysis suggests PPIs influence the magnitude of ICI efficacy, and this warrants further investigation.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Hopkins et al. (Tue,) studied this question.

synapsesocial.com/papers/69d74e0cb1cb92dd1bb8a662 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-20-1876

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab2020 · 111 citations
2Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer2019 · 348 citations
3What impact do the proton pump inhibitors have on the efficacy of immune check point inhibitors in metastatic malignant melanoma?2019 · 18 citations
4Proton pump inhibitors affect the gut microbiome2015 · 1,327 citations
5Proton pump inhibitors and response to immune check-point inhibitors: Single center study.2019 · 14 citations

Preguntar a la IA

Me gusta

Guardar